Reaction Details Report a problem with these data
Target
Glutaminase liver isoform, mitochondrial
Ligand
BDBM50548670
Substrate
n/a
Meas. Tech.
ChEMBL_2022796 (CHEMBL4676609)
IC50
>50000±n/a nM
Citation
Soth, MJ; Le, K; Di Francesco, ME; Hamilton, MM; Liu, G; Burke, JP; Carroll, CL; Kovacs, JJ; Bardenhagen, JP; Bristow, CA; Cardozo, M; Czako, B; de Stanchina, E; Feng, N; Garvey, JR; Gay, JP; Do, MKG; Greer, J; Han, M; Harris, A; Herrera, Z; Huang, S; Giuliani, V; Jiang, Y; Johnson, SB; Johnson, TA; Kang, Z; Leonard, PG; Liu, Z; McAfoos, T; Miller, M; Morlacchi, P; Mullinax, RA; Palmer, WS; Pang, J; Rogers, N; Rudin, CM; Shepard, HE; Spencer, ND; Theroff, J; Wu, Q; Xu, A; Yau, JA; Draetta, G; Toniatti, C; Heffernan, TP; Jones, P Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 63:12957-12977 (2020) [PubMed] Article
More Info.:
Target
Name:
Glutaminase liver isoform, mitochondrial
Synonyms:
3.5.1.2 | GA | GLS | GLS2 | GLSL_HUMAN | Glutaminase liver isoform, mitochondrial | L-glutaminase | L-glutamine amidohydrolase
Type:
PROTEIN
Mol. Mass.:
66331.64
Organism:
Homo sapiens
Description:
ChEMBL_117753
Residue:
602
Sequence:
MRSMKALQKALSRAGSHCGRGGWGHPSRSPLLGGGVRHHLSEAAAQGRETPHSHQPQHQDHDSSESGMLSRLGDLLFYTIAEGQERIPIHKFTTALKATGLQTSDPRLRDCMSEMHRVVQESSSGGLLDRDLFRKCVSSNIVLLTQAFRKKFVIPDFEEFTGHVDRIFEDVKELTGGKVAAYIPQLAKSNPDLWGVSLCTVDGQRHSVGHTKIPFCLQSCVKPLTYAISISTLGTDYVHKFVGKEPSGLRYNKLSLNEEGIPHNPMVNAGAIVVSSLIKMDCNKAEKFDFVLQYLNKMAGNEYMGFSNATFQSEKETGDRNYAIGYYLKEKKCFPKGVDMMAALDLYFQLCSVEVTCESGSVMAATLANGGICPITGESVLSAEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSAVSGAILLVVPNVMGMMCLSPPLDKLGNSHRGTSFCQKLVSLFNFHNYDNLRHCARKLDPRREGAEIRNKTVVNLLFAAYSGDVSALRRFALSAMDMEQKDYDSRTALHVAAAEGHIEVVKFLIEACKVNPFAKDRWGNIPLDDAVQFNHLEVVKLLQDYQDSYTLSETQAEAAAEALSKENLESMV